Now ClinicaltrialsDOTgov has two identical phase 2 studies entitled "Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand", NCT01683396 and NCT01882491. The only difference between them is in estimated completion date and estimated primary completion date. In the first study, dates are September 2013 and July 2013 and in the second one, they are April 2014 and February 2014. I guess, it means 7-months delay. Do not think it is the reason for recent SP drop.
Found that in a new company presentation they call it Supplemental Phase 2 (slide 21). Three doses of gevokizumab will be used instead of six. Also different are assessment methods. Question is why do they need it?
I'm still confused about the new type 1 diabetes trial NCT01788033. NCT00998699 is the one sponsored by the Juvenile Diabetes Research Foundation and we are supposed to hear something this summer, maybe even this month. I talked to a helpful person at the JDRF several months ago and I believe June was mentioned. Maybe this downdraft is because bad news is coming about that?